Compare NXT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXT | ARWR |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 12.4B |
| IPO Year | 2023 | 2009 |
| Metric | NXT | ARWR |
|---|---|---|
| Price | $79.30 | $65.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | ★ $115.67 | $83.40 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.66 | ★ 99.80 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,559,390,000.00 | $16,142,321.00 |
| Revenue This Year | $19.76 | N/A |
| Revenue Next Year | $11.96 | N/A |
| P/E Ratio | $73.95 | ★ N/A |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $73.07 | $34.38 |
| 52 Week High | $163.13 | $95.49 |
| Indicator | NXT | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 31.05 |
| Support Level | $77.86 | $61.60 |
| Resistance Level | $87.82 | $66.37 |
| Average True Range (ATR) | 3.51 | 3.91 |
| MACD | 0.41 | -0.80 |
| Stochastic Oscillator | 30.77 | 7.53 |
Nextpower (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextpower's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextpower has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.